World AIDS Day: New Research and Experts Available from Johns Hopkins Medicine

Credit: iStock


Charles Holmes, MD, MPH, has dedicated his career to leading government and private sector organizations to achieving their goals of improving health care around the world. He was previously chief medical officer and deputy director of global AIDS in the U.S. Office of the U.S. Department of the U.S. Department of Global AIDS and Health Diplomacy for the $ 6.5 billion Presidential Emergency Plan for Assistance to AIDS (PEPFAR), and served during the George W. Bush and Obama administrations.

In 2012, in a desire to get the “ground boots” experience in parts of the world that affected his Capitol Hill policies, Holmes moved his family to Zambia to head the Center for Infectious Disease Research in Zambia (CIDRZ), a system of about 300 research -centered clinics.

Shortly after taking up the position as director of CIDRZ, Holmes realized that the organization he had joined to lead was in operational turmoil. The finances are not in order, the funders are not happy with the performance and there is a lack of leadership. He knew he had to turn the organization around.

He and his colleagues developed a strategic business plan, including creating a more thoughtful and active board. The new board consists of three international members and seven local members. With the help of the new board, Holmes helped the organization set key priorities and set goals over five and ten years down the road, rather than shifting those goals toward funding.

Holmes has already handed over the leadership to Izukanji Sikazwe and now the center primarily focuses on research and care for people with HIV, tuberculosis, hepatitis B and cervical cancer.

Holmes wrote a op-ed, published in March 2017, on why the U.S. will continue to prioritize HIV prevention and treatment efforts in Africa.

Holmes and his colleagues also wrote a chapter on “Effectiveness and Effectiveness of Treatment as Prevention of HIV, ”Published November 9 at Disease Control Priorities (DCP3).


Charles W. Flexner, MD, a professor of medicine in the Divitions of Clinical Pharmacology and Infectious Diseases, and professor of pharmacology and molecular sciences at Johns Hopkins University School of Medicine. He is also professor of international health at the Johns Hopkins Bloomberg School of Public Health. Flexner is an expert in the basic and clinical pharmacology of drugs for HIV / AIDS and related infections, including viral hepatitis and tuberculosis.

Flexner’s research focuses on drug development and patient compliance, and it contributed to an editorial portion published in the July edition of Current Opinion on HIV and AIDS, which addresses the world’s need for a simple, easy -to -use antiretroviral regime. Today, 15 million to 17 million people worldwide are eligible for HIV treatment but do not have access to this treatment under the current “all-inclusive” guidelines established by the World Health Organization. Flexner suggests that an effective therapy should not be imperfect, but should be reached even for health habits that are less rooted. He argues that the possibility of extremely remote adverse effects is far greater than withholding a treatment in the world until it is completely, which is impossible, at best. An adoption of antiretroviral therapy worldwide could greatly reduce the rate of individuals infected with HIV and, possibly, permanently prevent the disease on a global scale.

Flexner is the co-chairman of 3rd The International Conference on Antiretroviral Drug Optimization (CADO3) in Johannesburg, South Africa, on December 1st. The conference will focus on ways to improve treatment options for people infected with HIV in low- and middle-income countries. Flexner will be used to answer questions via email.

Recent research:


  • New infections have decreased by 42 per cent in 30 communities within Rakai District, Uganda, the site of the first reported AIDS cases in East Africa.

Researchers and colleagues at Johns Hopkins report that HIV prevention methods, such as antiretroviral therapy, medical male circumcision, HIV testing and sex education, can effectively reduce the number of new infections in HIV in Ugandan communities. These results provide evidence that widespread implementation of prevention measures could significantly reduce HIV transmission worldwide, researchers report in the Dec. 1 issue of New England Journal of Medicine.

The new study included 34,000 people aged 15 to 49 from 30 communities who participated in the Rakai Community Cohort Study (RCCS). After implementing a joint HIV prevention program, the researchers found that new HIV infections in 30 communities fell from 11.7 to 6.6 new cases per 1,000 people per year- a decrease of 42 percent.

New research on the RCCS, established in 1994 in Rakai District in response to first known AIDS cases in East Africa. The RCCS brings findings such as a 60 percent reduction in HIV infection rates in circumcised men and the association between HIV viral load and transmission, which serves as the basis for HIV treatment as a precaution provided by the Emergency Plan for Presidential Care Science (PREPFAR) today.

The authors of the NEJM report M. Kate Grabowski, Ph.D., assistant professor of pathology at Johns Hopkins University School of Medicine and epidemiologist with Rakai Health Program, ug Larry W. Chang, MD, MPH, associate professor of medicine at Johns Hopkins University School of Medicine, says links between comprehensive HIV prevention programs and reduced infection rates among individuals have been shown in the past, but their research shows that programs can be successful at the population level. as well.

Grabowski and Chang will arrive for interviews related to the NEJM study and other topics related to HIV prevention.

Johns Hopkins Medicine will host the World AIDS Symposium on World AIDS Day, Dec. 1. This event is free and open to the public and the media is happy. More information to come.

When: Friday, Dec. 1, noon-2: 30 p.m.

Where: Becton-Dickinson Hall, 615 N. Wolfe St.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *